Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:11:07 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:BLUE - BLUEBIRD BIO INC - https://www.bluebirdbio.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BLUE - QHALTED4.97    28.50  3.20May 30Jun 0215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-02 08:34U:BLUENews Releasebluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
2025-05-30 08:30U:BLUENews ReleaseCarlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
2025-05-27 08:30U:BLUENews Releasebluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
2025-05-16 16:30U:BLUENews ReleaseCarlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
2025-05-14 08:30U:BLUENews ReleaseCarlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
2025-05-09 08:30U:BLUENews ReleaseImportant Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
2025-05-05 16:00U:BLUENews ReleaseCarlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
2025-04-16 08:00U:BLUENews Releasebluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
2025-03-28 16:15U:BLUENews Releasebluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
2025-02-21 07:30U:BLUENews Releasebluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
2024-12-08 12:30U:BLUENews Releasebluebird bio Presents Positive Long-Term Data On LYFGENIA(TM) (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
2024-12-07 12:00U:BLUENews ReleaseLong-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for beta-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
2024-12-04 16:05U:BLUENews Releasebluebird bio Announces 1-for-20 Reverse Stock Split
2024-12-04 08:47U:BLUENews Releasebluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
2024-11-14 07:00U:BLUENews Releasebluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
2024-11-06 16:15U:BLUENews Releasebluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
2024-11-05 09:05U:BLUENews Releasebluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
2024-10-04 16:05U:BLUENews Releasebluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-27 16:30U:BLUENews Releasebluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
2024-09-24 07:00U:BLUENews Releasebluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025